Last reviewed · How we verify
Denosin® and Xyzal® — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Denosin® and Xyzal® (Denosin® and Xyzal®) — Lotus Pharmaceutical.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Denosin® and Xyzal® TARGET | Denosin® and Xyzal® | Lotus Pharmaceutical | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Denosin® and Xyzal® CI watch — RSS
- Denosin® and Xyzal® CI watch — Atom
- Denosin® and Xyzal® CI watch — JSON
- Denosin® and Xyzal® alone — RSS
Cite this brief
Drug Landscape (2026). Denosin® and Xyzal® — Competitive Intelligence Brief. https://druglandscape.com/ci/denosin-and-xyzal. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab